{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:59:43Z","timestamp":1780635583491,"version":"3.54.1"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009395","name":"CancerCare Manitoba Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009395","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008794","name":"Research Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010318","name":"University of Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010318","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000238","name":"Brain Tumour Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Medulloblastoma (MB) is the most common childhood brain cancer, with Group 3 (G3) as the most aggressive subgroup, being prone to relapse and treatment resistance. A small subset of stem-like cells contributes to this recurrence, but the mechanisms behind their transformation are not fully understood. In this study, we employed therapeutically relevant in vitro and in vivo chemoradiotherapy (CRT) models of G3 MB and discovered a significant activation of SRC kinase following CRT treatment, while other kinases such as AKT and ERK were unaffected. Remarkably, SRC activation was exclusive to G3 MB cells and was absent in the less aggressive Sonic Hedgehog and Group 4 MB, as well as in normal brain cells. SRC activation in CRT-treated G3 MB cell and tumors corresponded with increased stemness, as evidenced by elevated levels of stemness factors SOX2, NOTCH1, OCT4, Nanog and phosphorylated STAT3, alongside a reduction in the differentiation marker \u03b2III-tubulin\/TUBB3. Conversely,\n                    <jats:italic>SRC<\/jats:italic>\n                    knockout or pharmacological inhibition promoted differentiation and reduced aggressiveness in CRT-resistant G3 MB cells, which could be rescued by re-expression of SRC in\n                    <jats:italic>SRC<\/jats:italic>\n                    knockout cells. Additionally, SRC inhibition significantly reduced the viability of CRT-treated G3 MB cells by inducing both apoptosis and necroptosis, while sparing the proliferation and stem-like properties of normal neural stem cells, indicating a promising toxicity profile. Importantly, in a therapeutically relevant orthotopic G3 MB model, administration of the re-purposed blood-brain-barrier permeable SRC inhibitor, Saracatinib, in conjunction with CRT, significantly reduced tumor burden and improved animal survival compared to CRT treatment alone without any neurotoxic side effects. Overall, our results underscore the pivotal role of SRC in enhancing stemness and aggressive behavior in CRT-resistant recurrent G3 MB. Targeting SRC not only promotes cell death through apoptosis and necroptosis but also encourages differentiation, positioning it as a promising therapeutic target for rapid clinical interventions.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08751-9","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T03:13:57Z","timestamp":1777000437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting SRC enhances differentiation and promotes multifaceted cell death mechanisms in recurrent group 3 medulloblastoma"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5260-349X","authenticated-orcid":false,"given":"Helgi","family":"Kuzmychova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujala","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3985-0703","authenticated-orcid":false,"given":"Emma","family":"Martell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akaljot","family":"Grewal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charul","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayshana","family":"Ramnauth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esha","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal","family":"Senthil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-5300","authenticated-orcid":false,"given":"Sheila K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3269-8100","authenticated-orcid":false,"given":"Tanveer","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"8751_CR1","first-page":"381","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA A Cancer J Clin. 2021;71:381\u2013406.","journal-title":"CA A Cancer J Clin"},{"key":"8751_CR2","unstructured":"Statistics Canada and Public Health Agency of Canada. The Canadian Cancer Statistics Advisory Committee, in collaboration with the Canadian Cancer Society. Canadian Cancer Statistics. 2023. pp. 1\u2013114."},{"key":"8751_CR3","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1200\/JCO.2009.27.4324","volume":"29","author":"PA Northcott","year":"2011","unstructured":"Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011;29:1408\u201314.","journal-title":"J Clin Oncol"},{"key":"8751_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2176\/nmc.ra.2016-0016","volume":"56","author":"N Kijima","year":"2016","unstructured":"Kijima N, Kanemura Y. Molecular classification of medulloblastoma. Neurol Med Chir. 2016;56:687\u201397.","journal-title":"Neurol Med Chir"},{"key":"8751_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1586\/ern.12.66","volume":"12","author":"PA Northcott","year":"2012","unstructured":"Northcott PA, Dubuc AM, Pfister S, Taylor MD. Molecular subgroups of medulloblastoma. Expert Rev Neurother. 2012;12:871\u201384.","journal-title":"Expert Rev Neurother"},{"key":"8751_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50554-z","volume":"15","author":"S Godbole","year":"2024","unstructured":"Godbole S, Vo\u00df H, Gocke A, Schlumbohm S, Schumann Y, Peng B, et al. Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level. Nat Commun. 2024;15:6237.","journal-title":"Nat Commun"},{"key":"8751_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s11910-023-01316-9","volume":"23","author":"K Jackson","year":"2023","unstructured":"Jackson K, Packer RJ. Recent advances in pediatric medulloblastoma. Curr Neurol Neurosci Rep. 2023;23:841\u20138.","journal-title":"Curr Neurol Neurosci Rep"},{"key":"8751_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2174\/1570159X15666171129111324","volume":"16","author":"S Khatua","year":"2018","unstructured":"Khatua S, Song A, Sridhar DC, Mack SC. Childhood medulloblastoma: current therapies, emerging molecular landscape and newer therapeutic insights. Curr Neuropharmacol. 2018;16:1045\u201358.","journal-title":"Curr Neuropharmacol"},{"key":"8751_CR9","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1200\/JCO.22.02466","volume":"41","author":"H Coltin","year":"2023","unstructured":"Coltin H, Pequeno P, Liu N, Tsang DS, Gupta S, Taylor MD, et al. The burden of surviving childhood medulloblastoma: a population-based, matched cohort study in Ontario, Canada. J Clin Oncol. 2023;41:2372\u201381.","journal-title":"J Clin Oncol"},{"key":"8751_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-016-1569-6","volume":"131","author":"V Ramaswamy","year":"2016","unstructured":"Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131:821\u201331.","journal-title":"Acta Neuropathol"},{"key":"8751_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1470-2045(13)70449-2","volume":"14","author":"V Ramaswamy","year":"2013","unstructured":"Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho Y-J, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013;14:1200\u20137.","journal-title":"Lancet Oncol"},{"key":"8751_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2352-4642(20)30246-7","volume":"4","author":"RM Hill","year":"2020","unstructured":"Hill RM, Richardson S, Schwalbe EC, Hicks D, Lindsey JC, Crosier S, et al. Time, pattern, and outcome of medulloblastoma relapse and their association with tumour biology at diagnosis and therapy: a multicentre cohort study. Lancet Child Adolesc Health. 2020;4:865\u201374.","journal-title":"Lancet Child Adolesc Health"},{"key":"8751_CR13","doi-asserted-by":"publisher","first-page":"108673","DOI":"10.1016\/j.pharmthera.2024.108673","volume":"260","author":"K Peterson","year":"2024","unstructured":"Peterson K, Turos-Cabal M, Salvador AD, Palomo-Caturla I, Howell AJ, Vieira ME, et al. Mechanistic insights into medulloblastoma relapse. Pharmacol Ther. 2024;260:108673.","journal-title":"Pharmacol Ther"},{"key":"8751_CR14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/ng.3838","volume":"49","author":"AS Morrissy","year":"2017","unstructured":"Morrissy AS, Cavalli FMG, Remke M, Ramaswamy V, Shih DJH, Holgado BL, et al. Spatial heterogeneity in medulloblastoma. Nat Genet. 2017;49:780\u20138.","journal-title":"Nat Genet"},{"key":"8751_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-54709-w","volume":"15","author":"I Kats","year":"2024","unstructured":"Kats I, Simovic-Lorenz M, Schreiber HS, Sant P, Mallm JP, K\u00f6rber V, et al. Spatio-temporal transcriptomics of chromothriptic SHH-medulloblastoma identifies multiple genetic clones that resist treatment and drive relapse. Nat Commun. 2024;15:1\u201319.","journal-title":"Nat Commun"},{"key":"8751_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","volume":"18","author":"SK Mitra","year":"2006","unstructured":"Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006;18:516\u201323.","journal-title":"Curr Opin Cell Biol"},{"key":"8751_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.gde.2010.10.012","volume":"21","author":"J Brognard","year":"2011","unstructured":"Brognard J, Hunter T. Protein kinase signaling networks in cancer. Curr Opin Genet Dev. 2011;21:4\u201311.","journal-title":"Curr Opin Genet Dev"},{"key":"8751_CR18","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nrm2039","volume":"7","author":"NK Tonks","year":"2006","unstructured":"Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7:833\u201346.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8751_CR19","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda \u00c1R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537\u201349.","journal-title":"Nat Rev Cancer"},{"key":"8751_CR20","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen P, Cross D, J\u00e4nne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20:551\u201369.","journal-title":"Nat Rev Drug Discov"},{"key":"8751_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","volume":"36","author":"P Wu","year":"2015","unstructured":"Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36:422\u201339.","journal-title":"Trends Pharmacol Sci"},{"key":"8751_CR22","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"R Roskoski","year":"2024","unstructured":"Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update. Pharmacol Res. 2024;200:107059.","journal-title":"Pharmacol Res"},{"key":"8751_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms25084565","volume":"25","author":"R Ramos","year":"2024","unstructured":"Ramos R, Vale N. Dual drug repurposing: the example of saracatinib. Int J Mol Sci. 2024;25:1\u201313.","journal-title":"Int J Mol Sci"},{"key":"8751_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20379-7","volume":"12","author":"R Fang","year":"2021","unstructured":"Fang R, Chen X, Zhang S, Shi H, Ye Y, Shi H, et al. EGFR\/SRC\/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021;12:177.","journal-title":"Nat Commun"},{"key":"8751_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21207437","volume":"21","author":"S Alcal\u00e1","year":"2020","unstructured":"Alcal\u00e1 S, Mayoral-Varo V, Ruiz-Ca\u00f1as L, L\u00f3pez-Gil JC, Heeschen C, Mart\u00edn-P\u00e9rez J, et al. Targeting src kinase signaling in pancreatic cancer stem cells. Int J Mol Sci. 2020;21:1\u201322.","journal-title":"Int J Mol Sci"},{"key":"8751_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3892\/ijo.2014.2432","volume":"45","author":"X Han","year":"2014","unstructured":"Han X, Zhang W, Yang X, Wheeler CG, Langford CP, Wu L, et al. The role of Src family kinases in growth and migration of glioma stem cells. Int J Oncol. 2014;45:302\u201310.","journal-title":"Int J Oncol"},{"key":"8751_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/jcs.250134","volume":"135","author":"SB Serizier","year":"2022","unstructured":"Serizier SB, Peterson JS, McCall K. Non-autonomous cell death induced by the Draper phagocytosis receptor requires signaling through the JNK and SRC pathways. J Cell Sci. 2022;135:1\u20139.","journal-title":"J Cell Sci"},{"key":"8751_CR28","doi-asserted-by":"publisher","first-page":"19112","DOI":"10.1074\/jbc.M709882200","volume":"283","author":"H Yamaguchi","year":"2008","unstructured":"Yamaguchi H, Woods NT, Dorsey JF, Takahashi Y, Gjertsen NR, Yeatman T, et al. Src directly phosphorylates Bif-1 and prevents its interaction with Bax and the initiation of anoikis. J Biol Chem. 2008;283:19112\u20138.","journal-title":"J Biol Chem"},{"key":"8751_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11060-012-0978-1","volume":"110","author":"T Milde","year":"2012","unstructured":"Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, et al. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J Neuro-Oncol. 2012;110:335\u201348.","journal-title":"J Neuro-Oncol"},{"key":"8751_CR30","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/1078-0432.CCR-13-2281","volume":"20","author":"P Bandopadhayay","year":"2014","unstructured":"Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20:912\u201325.","journal-title":"Clin Cancer Res"},{"key":"8751_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-016-2170-z","volume":"16","author":"S Dietl","year":"2016","unstructured":"Dietl S, Schwinn S, Dietl S, Riedel S, Deinlein F, Rutkowski S, et al. MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. BMC Cancer. 2016;16:1\u201313.","journal-title":"BMC Cancer"},{"key":"8751_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jbiotec.2016.07.028","volume":"236","author":"DP Ivanov","year":"2016","unstructured":"Ivanov DP, Coyle B, Walker DA, Grabowska AM. In vitro models of medulloblastoma: choosing the right tool for the job. J Biotechnol. 2016;236:10\u201325.","journal-title":"J Biotechnol"},{"key":"8751_CR33","first-page":"358","volume":"126","author":"JQFH Trojanowski","year":"1987","unstructured":"Trojanowski JQFH, Burger PC, Bigner DD. A rapidly dividing human medulloblastoma cell line (D283 MED) expresses all three neurofilament subunits. Am Assoc Pathol. 1987;126:358\u201363.","journal-title":"Am Assoc Pathol"},{"key":"8751_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17953-4","volume":"11","author":"B Manoranjan","year":"2020","unstructured":"Manoranjan B, Venugopal C, Bakhshinyan D, Adile AA, Richards L, Kameda-Smith MM, et al. Wnt activation as a therapeutic strategy in medulloblastoma. Nat Commun. 2020;11:4323.","journal-title":"Nat Commun"},{"key":"8751_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03646-9","volume":"25","author":"J Klementov\u00e1","year":"2025","unstructured":"Klementov\u00e1 J, Jaro\u0161ov\u00e1 \u0160, Danilov\u00e1 I, Farn\u00edkov\u00e1 M, Novotn\u00fd J, Dav\u00eddkov\u00e1 M, et al. Comparative analysis of pediatric SHH medulloblastoma DAOY spheres and adherent monolayers: implications for medulloblastoma research. Cancer Cell Int. 2025;25:22.","journal-title":"Cancer Cell Int"},{"key":"8751_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22294-x","volume":"12","author":"SC Taylor","year":"2022","unstructured":"Taylor SC, Rosselli-Murai LK, Crobeddu B, Plante I. A critical path to producing high-quality, reproducible data from quantitative western blot experiments. Sci Rep. 2022;12:17599.","journal-title":"Sci Rep"},{"key":"8751_CR37","doi-asserted-by":"publisher","first-page":"101628","DOI":"10.1016\/j.xpro.2022.101628","volume":"3","author":"Y Suk","year":"2022","unstructured":"Suk Y, Kieliszek A, Mobilio D, Venugopal C, Singh SK. Derivation and culturing of neural stem cells from human embryonic brain tissue. STAR Protoc. 2022;3:101628.","journal-title":"STAR Protoc"},{"key":"8751_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2020.113608","volume":"593","author":"L Pillai-Kastoori","year":"2020","unstructured":"Pillai-Kastoori L, Schutz-Geschwender AR, Harford JA. A systematic approach to quantitative Western blot analysis. Anal Biochem. 2020;593:113608.","journal-title":"Anal Biochem"},{"key":"8751_CR39","doi-asserted-by":"publisher","first-page":"e87293","DOI":"10.1371\/journal.pone.0087293","volume":"9","author":"A Degasperi","year":"2014","unstructured":"Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN. Evaluating strategies to normalise biological replicates of Western blot data. PLoS ONE. 2014;9:e87293.","journal-title":"PLoS ONE"},{"key":"8751_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40478-023-01504-1","volume":"11","author":"K Okonechnikov","year":"2023","unstructured":"Okonechnikov K, Federico A, Schrimpf D, Sievers P, Sahm F, Koster J, et al. Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses. Acta Neuropathol Commun. 2023;11:7.","journal-title":"Acta Neuropathol Commun"},{"key":"8751_CR41","first-page":"1","volume":"11","author":"M Zhao","year":"2016","unstructured":"Zhao M, Finlay D, Zharkikh I, Vuori K. Novel role of Src in priming Pyk2 phosphorylation. PLoS ONE. 2016;11:1\u201314.","journal-title":"PLoS ONE"},{"key":"8751_CR42","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s11427-022-2216-x","volume":"66","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zhao D, Zhang L, Xiao Y, Wu Q, Wang Y, et al. Src heterodimerically activates Lyn or Fyn to serve as targets for the diagnosis and treatment of esophageal squamous cell carcinoma. Sci China Life Sci. 2023;66:1245\u201363.","journal-title":"Sci China Life Sci"},{"key":"8751_CR43","doi-asserted-by":"publisher","first-page":"10754","DOI":"10.1016\/S0021-9258(18)82049-X","volume":"268","author":"O Nakanishi","year":"1993","unstructured":"Nakanishi O, Shibasaki F, Hidaka M, Homma Y, Takenawa T. Phospholipase C-\u03b31 associates with viral and cellular src kinases. J Biol Chem. 1993;268:10754\u20139.","journal-title":"J Biol Chem"},{"key":"8751_CR44","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1158\/0008-5472.CAN-18-0267","volume":"78","author":"MA Qazi","year":"2018","unstructured":"Qazi MA, Vora P, Venugopal C, Adams J, Singh M, Hu A, et al. Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces the growth of recurrent glioblastoma. Cancer Res. 2018;78:5023\u201337.","journal-title":"Cancer Res"},{"key":"8751_CR45","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1038\/s41467-023-38049-9","volume":"14","author":"E Martell","year":"2023","unstructured":"Martell E, Kuzmychova H, Kaul E, Senthil H, Chowdhury SR, Morrison LC, et al. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. Nat Commun. 2023;14:2502.","journal-title":"Nat Commun"},{"key":"8751_CR46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ccr.2011.12.021","volume":"21","author":"Y Pei","year":"2012","unstructured":"Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, et al. An animal model of MYC-driven medulloblastoma. Cancer Cell. 2012;21:155\u201367.","journal-title":"Cancer Cell"},{"key":"8751_CR47","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccell.2018.08.002","volume":"34","author":"A Forget","year":"2018","unstructured":"Forget A, Martignetti L, Puget S, Calzone L, Brabetz S, Picard D, et al. Aberrant ERBB4-SRC signaling as a hallmark of group 4 medulloblastoma revealed by integrative phosphoproteomic profiling. Cancer Cell. 2018;34:379\u201395.e377.","journal-title":"Cancer Cell"},{"key":"8751_CR48","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.cell.2013.01.036","volume":"152","author":"M Snuderl","year":"2013","unstructured":"Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, et al. Targeting placental growth factor\/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013;152:1065\u201376.","journal-title":"Cell"},{"key":"8751_CR49","doi-asserted-by":"crossref","unstructured":"Prados MD. Current strategies for management of medulloblastoma. Diagnostics. 2023;13:2622.","DOI":"10.3390\/diagnostics13162622"},{"key":"8751_CR50","doi-asserted-by":"crossref","unstructured":"Lai SW, Bamodu OA, Tsai WC, Chang YM, Lee WH, Yeh CT, et al. The therapeutic targeting of the FGFR1\/Src\/NF-\u03baB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity. Clin Exp Metastasis. 2018;35:663\u201377.","DOI":"10.1007\/s10585-018-9919-5"},{"key":"8751_CR51","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.ccell.2017.05.005","volume":"31","author":"FMG Cavalli","year":"2017","unstructured":"Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell. 2017;31:737\u201354.e736.","journal-title":"Cancer Cell"},{"key":"8751_CR52","doi-asserted-by":"crossref","unstructured":"Martell E, Kuzmychova H, Senthil H, Chawla U, Kaul E, Grewal A, et al. Disease-stage-specific role of the mitochondrial pyruvate carrier suppresses differentiation in temozolomide- and radiation-treated glioblastoma. Neuro Oncol. 2025;27:1193\u20131209.","DOI":"10.1093\/neuonc\/noaf008"},{"key":"8751_CR53","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1158\/0008-5472.CAN-18-1787","volume":"79","author":"R Tao","year":"2019","unstructured":"Tao R, Murad N, Xu Z, Zhang P, Okonechnikov K, Kool M, et al. MYC drives group 3 medulloblastoma through the transformation of Sox2(+) astrocyte progenitor cells. Cancer Res. 2019;79:1967\u201380.","journal-title":"Cancer Res"},{"key":"8751_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11060-011-0647-9","volume":"106","author":"CO Rodini","year":"2012","unstructured":"Rodini CO, Suzuki DE, Saba-Silva N, Cappellano A, de Souza JE, Cavalheiro S, et al. Expression analysis of stem cell-related genes reveals OCT4 as a predictor of poor clinical outcome in medulloblastoma. J Neurooncol. 2012;106:71\u20139.","journal-title":"J Neurooncol"},{"key":"8751_CR55","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1158\/0008-5472.CAN-10-3395","volume":"71","author":"P Bhoopathi","year":"2011","unstructured":"Bhoopathi P, Chetty C, Dontula R, Gujrati M, Dinh DH, Rao JS, et al. SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1\/STAT3 pathway. Cancer Res. 2011;71:4908\u201319.","journal-title":"Cancer Res"},{"key":"8751_CR56","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1038\/emboj.2010.131","volume":"29","author":"A Po","year":"2010","unstructured":"Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G, et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J. 2010;29:2646\u201358.","journal-title":"EMBO J"},{"key":"8751_CR57","doi-asserted-by":"publisher","first-page":"55624","DOI":"10.18632\/oncotarget.10954","volume":"7","author":"EJ Seo","year":"2016","unstructured":"Seo EJ, Kim DK, Jang IH, Choi EJ, Shin SH, Lee SI, et al. Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer. Oncotarget. 2016;7:55624\u201338.","journal-title":"Oncotarget"},{"key":"8751_CR58","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.3390\/cells9122677","volume":"9","author":"PA Shah","year":"2020","unstructured":"Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, et al. Notch1 signaling in head and neck squamous cell carcinoma. Cells. 2020;9:2677.","journal-title":"Cells"},{"key":"8751_CR59","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41593-018-0285-z","volume":"22","author":"J Wang","year":"2019","unstructured":"Wang J, Xu SL, Duan JJ, Yi L, Guo YF, Shi Y, et al. Invasion of white matter tracts by glioma stem cells is regulated by a NOTCH1-SOX2 positive-feedback loop. Nat Neurosci. 2019;22:91\u2013105.","journal-title":"Nat Neurosci"},{"key":"8751_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107782","volume":"31","author":"Y Cheng","year":"2020","unstructured":"Cheng Y, Liao S, Xu G, Hu J, Guo D, Du F, et al. NeuroD1 Dictates tumor cell differentiation in medulloblastoma. Cell Rep. 2020;31:107782.","journal-title":"Cell Rep"},{"key":"8751_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17357-4","volume":"11","author":"J Zagozewski","year":"2020","unstructured":"Zagozewski J, Shahriary GM, Morrison LC, Saulnier O, Stromecki M, Fresnoza A, et al. An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nat Commun. 2020;11:3627.","journal-title":"Nat Commun"},{"key":"8751_CR62","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/s43018-021-00287-5","volume":"2","author":"F Mauri","year":"2021","unstructured":"Mauri F, Schepkens C, Lapouge G, Drogat B, Song Y, Pastushenko I, et al. NR2F2 controls the malignant squamous cell carcinoma state by promoting stemness and invasion and repressing differentiation. Nat Cancer. 2021;2:1152\u201369.","journal-title":"Nat Cancer"},{"key":"8751_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cddis.2013.509","volume":"5","author":"Y Fu","year":"2014","unstructured":"Fu Y, Yang G, Zhu F, Peng C, Li W, Li H, et al. Antioxidants decrease the apoptotic effect of 5-Fu in colon cancer by regulating Src-dependent caspase-7 phosphorylation. Cell Death Dis. 2014;5:1\u201310.","journal-title":"Cell Death Dis"},{"key":"8751_CR64","doi-asserted-by":"publisher","first-page":"112261","DOI":"10.1016\/j.yexcr.2020.112261","volume":"396","author":"X Li","year":"2020","unstructured":"Li X, Tao Z, Wang H, Deng Z, Zhou Y, Du Z. Dual inhibition of Src and PLK1 regulates stemness and induces apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs). Exp Cell Res. 2020;396:112261.","journal-title":"Exp Cell Res"},{"key":"8751_CR65","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.3892\/or.2016.5156","volume":"36","author":"JF Wu","year":"2016","unstructured":"Wu JF, Ji J, Dong SY, Li BB, Yu ML, Wu DD, et al. Gefitinib enhances oxaliplatin-induced apoptosis mediated by Src and PKC-modulated gap junction function. Oncol Rep. 2016;36:3251\u20138.","journal-title":"Oncol Rep"},{"key":"8751_CR66","doi-asserted-by":"crossref","unstructured":"Wang H, Han S, Xie J, Zhao R, Li S, Li J. IL-17A exacerbates caspase-12-dependent neuronal apoptosis following ischemia through the Src-PLC\u03b3-calpain pathway. Exp Neurol. 2024;379:114863.","DOI":"10.1016\/j.expneurol.2024.114863"},{"key":"8751_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez V, Hern\u00e1ndez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front Oncol. 2019;9:1\u201310.","journal-title":"Front Oncol"},{"key":"8751_CR68","doi-asserted-by":"publisher","first-page":"9018","DOI":"10.1128\/MCB.20.23.9018-9027.2000","volume":"20","author":"RA Blake","year":"2000","unstructured":"Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, et al. SU6656, a selective Src family kinase inhibitor, is used to probe growth factor signaling. Mol Cell Biol. 2000;20:9018\u201327.","journal-title":"Mol Cell Biol"},{"key":"8751_CR69","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1038\/d41586-018-06704-7","volume":"561","author":"J Gould","year":"2018","unstructured":"Gould J. Breaking down the epidemiology of brain cancer. Nature. 2018;561:S40\u20131.","journal-title":"Nature"},{"key":"8751_CR70","first-page":"910","volume":"14","author":"M Kapalczynska","year":"2018","unstructured":"Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018;14:910\u20139.","journal-title":"Arch Med Sci"},{"key":"8751_CR71","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1054\/bjoc.1999.1169","volume":"82","author":"Ukcccr.","year":"2000","unstructured":"Ukcccr. UKCCCR guidelines for the use of cell lines in cancer research. Br J Cancer. 2000;82:1495\u2013509.","journal-title":"Br J Cancer"},{"key":"8751_CR72","doi-asserted-by":"crossref","unstructured":"Grewal A, Martell E, Kuzmychova H, Chawla U, Jain C, Ramnauth K, et al. A functionally relevant model for interrogating brain tumor-endothelial cell interactions. J Neurosci Methods. 2025;427:110657.","DOI":"10.1016\/j.jneumeth.2025.110657"},{"key":"8751_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101407","volume":"20","author":"MD Tang-Schomer","year":"2022","unstructured":"Tang-Schomer MD, Chandok H, Wu WB, Lau CC, Bookland MJ, George J. 3D patient-derived tumor models to recapitulate pediatric brain tumors In Vitro. Transl Oncol. 2022;20:101407.","journal-title":"Transl Oncol"},{"key":"8751_CR74","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","volume":"28","author":"M Shariati","year":"2019","unstructured":"Shariati M, Meric-Bernstam F. Targeting AKT for cancer therapy. Expert Opin Investig Drugs. 2019;28:977\u201388.","journal-title":"Expert Opin Investig Drugs"},{"key":"8751_CR75","doi-asserted-by":"crossref","unstructured":"Iqbal N, Iqbal N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027.","DOI":"10.1155\/2014\/357027"},{"key":"8751_CR76","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s11060-023-04372-w","volume":"163","author":"AA Adile","year":"2023","unstructured":"Adile AA, Bakhshinyan D, Suk Y, Uehling D, Saini M, Aman A, et al. An effective kinase inhibition strategy for metastatic recurrent childhood medulloblastoma. J Neuro Oncol. 2023;163:635\u201345.","journal-title":"J Neuro Oncol"},{"key":"8751_CR77","doi-asserted-by":"publisher","first-page":"25113","DOI":"10.18632\/oncotarget.7159","volume":"7","author":"Y Jin","year":"2016","unstructured":"Jin Y, Cai Q, Shenoy AK, Lim S, Zhang Y, Charles S, et al. Src drives the warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation. Oncotarget. 2016;7:25113\u201324.","journal-title":"Oncotarget"},{"key":"8751_CR78","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.2147\/OTT.S245749","volume":"13","author":"J Zhou","year":"2020","unstructured":"Zhou J, Xu M, Le K, Ming J, Guo H, Ruan S, et al. SRC promotes tamoxifen resistance in breast cancer via up-regulating SIRT1. OncoTargets Ther. 2020;13:4635\u201347.","journal-title":"OncoTargets Ther"},{"key":"8751_CR79","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41556-023-01093-0","volume":"25","author":"H Zou","year":"2023","unstructured":"Zou H, Poore B, Brown EE, Qian J, Xie B, Asimakidou E, et al. A neurodevelopmental epigenetic programme mediated by SMARCD3\u2013DAB1\u2013Reelin signalling is hijacked to promote medulloblastoma metastasis. Nat Cell Biol. 2023;25:493\u2013507.","journal-title":"Nat Cell Biol"},{"key":"8751_CR80","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1038\/sj.onc.1208158","volume":"23","author":"LV Kalia","year":"2004","unstructured":"Kalia LV, Gingrich JR, Salter MW. Src in synaptic transmission and plasticity. Oncogene. 2004;23:8007\u201316.","journal-title":"Oncogene"},{"key":"8751_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-12-18","volume":"12","author":"L Yuan","year":"2013","unstructured":"Yuan L, Zhang H, Liu J, Rubin JB, Cho YJ, Shu HK, et al. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. Mol Cancer. 2013;12:1\u20131.","journal-title":"Mol Cancer"},{"key":"8751_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40478-023-01604-y","volume":"11","author":"E Martell","year":"2023","unstructured":"Martell E, Kuzmychova H, Senthil H, Kaul E, Chokshi CR, Venugopal C, et al. Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations. Acta Neuropathol Commun. 2023;11:110.","journal-title":"Acta Neuropathol Commun"},{"key":"8751_CR83","doi-asserted-by":"publisher","first-page":"101914","DOI":"10.1016\/j.xcrm.2024.101914","volume":"6","author":"H Liu","year":"2025","unstructured":"Liu H, Zhang J, Wang Z, Wang W, Han D, Chen X, et al. High cellular plasticity state of medulloblastoma local recurrence and distant dissemination. Cell Rep Med. 2025;6:101914.","journal-title":"Cell Rep Med"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08751-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08751-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:02:43Z","timestamp":1780632163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08751-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8751"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08751-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"543"}}